IL184008A - 4-cycloalkyl-substituted tetrahydroquinoline derivatives and use thereof as medicaments - Google Patents
4-cycloalkyl-substituted tetrahydroquinoline derivatives and use thereof as medicamentsInfo
- Publication number
- IL184008A IL184008A IL184008A IL18400807A IL184008A IL 184008 A IL184008 A IL 184008A IL 184008 A IL184008 A IL 184008A IL 18400807 A IL18400807 A IL 18400807A IL 184008 A IL184008 A IL 184008A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- formula
- inhibitors
- salts
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004060997A DE102004060997A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| DE102004061000A DE102004061000A1 (de) | 2004-12-18 | 2004-12-18 | Chemische Verbindung und ihre Verwendung |
| PCT/EP2005/013490 WO2006063828A1 (de) | 2004-12-18 | 2005-12-15 | 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL184008A0 IL184008A0 (en) | 2007-10-31 |
| IL184008A true IL184008A (en) | 2012-03-29 |
Family
ID=35841894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL184008A IL184008A (en) | 2004-12-18 | 2007-06-18 | 4-cycloalkyl-substituted tetrahydroquinoline derivatives and use thereof as medicaments |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8124775B2 (enExample) |
| EP (1) | EP1828137B1 (enExample) |
| JP (1) | JP5132317B2 (enExample) |
| KR (1) | KR20070090248A (enExample) |
| AR (1) | AR055011A1 (enExample) |
| AT (1) | ATE555097T1 (enExample) |
| AU (1) | AU2005315770B2 (enExample) |
| BR (1) | BRPI0519602A2 (enExample) |
| CA (1) | CA2591397A1 (enExample) |
| CU (1) | CU23452B7 (enExample) |
| CY (1) | CY1112887T1 (enExample) |
| DK (1) | DK1828137T3 (enExample) |
| DO (1) | DOP2005000259A (enExample) |
| ES (1) | ES2384980T3 (enExample) |
| GT (1) | GT200500377A (enExample) |
| IL (1) | IL184008A (enExample) |
| MA (1) | MA29100B1 (enExample) |
| MX (1) | MX2007007188A (enExample) |
| NO (1) | NO20073146L (enExample) |
| PE (1) | PE20060767A1 (enExample) |
| PL (1) | PL1828137T3 (enExample) |
| PT (1) | PT1828137E (enExample) |
| RU (1) | RU2393151C2 (enExample) |
| SI (1) | SI1828137T1 (enExample) |
| TW (1) | TW200635900A (enExample) |
| UY (1) | UY29276A1 (enExample) |
| WO (1) | WO2006063828A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005324127A1 (en) * | 2004-12-18 | 2006-07-13 | Bayer Healthcare Ag | (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors |
| DE102006012548A1 (de) * | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
| ATE520696T1 (de) * | 2008-03-05 | 2011-09-15 | Boehringer Ingelheim Int | Tricyclische pyridinderivate, solche verbindungen enthaltende medikamente, ihre verwendung und verfahren zu ihrer herstellung |
| MA34007B1 (fr) | 2010-02-19 | 2013-02-01 | Boehringer Ingelheim Int | Derives de pyridine tricycliques medicaments contenant ces composes leur utilisation et leur procede de preparation |
| US9187450B2 (en) * | 2010-07-09 | 2015-11-17 | Daiichi Sankyo Company, Limited | Substituted pyridine compound |
| WO2012110599A1 (en) | 2011-02-17 | 2012-08-23 | Boehringer Ingelheim International Gmbh | Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation |
| US9150583B2 (en) | 2011-08-17 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
| US9321747B2 (en) | 2012-01-06 | 2016-04-26 | Daiichi Sankyo Company, Limited | Acid addition salt of substituted pyridine compound |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4128681A1 (de) * | 1991-08-29 | 1993-03-04 | Bayer Ag | Substituierte mandelsaeurederivate, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| DE19610932A1 (de) | 1996-03-20 | 1997-09-25 | Bayer Ag | 2-Aryl-substituierte Pyridine |
| DE19627430A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Bicyclisch kondensierte Pyridine |
| US6207671B1 (en) | 1996-07-08 | 2001-03-27 | Bayer Aktiengesellschaft | Cycloalkano-pyridines |
| HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
| DE19704244A1 (de) | 1997-02-05 | 1998-08-06 | Bayer Ag | 5-Hydroxy-alkyl substituierte Phenyle |
| DE19709125A1 (de) | 1997-03-06 | 1998-09-10 | Bayer Ag | Substituierte Chinoline |
| MA24643A1 (fr) * | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
| DE19741051A1 (de) | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
| DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
| DE19935966A1 (de) | 1999-07-30 | 2001-02-01 | Bayer Ag | Verfahren zur Reduktion von Ketoalkoholen |
| DE10148436A1 (de) | 2001-10-01 | 2003-04-17 | Bayer Ag | Tetrahydrochinoline |
| DE10250687A1 (de) | 2002-10-31 | 2004-05-13 | Bayer Ag | 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung |
| AU2005324127A1 (en) * | 2004-12-18 | 2006-07-13 | Bayer Healthcare Ag | (5S) -3-[(S)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as CETP inhibitors |
-
2005
- 2005-12-15 WO PCT/EP2005/013490 patent/WO2006063828A1/de not_active Ceased
- 2005-12-15 KR KR1020077016219A patent/KR20070090248A/ko not_active Ceased
- 2005-12-15 EP EP05820528A patent/EP1828137B1/de not_active Expired - Lifetime
- 2005-12-15 BR BRPI0519602-7A patent/BRPI0519602A2/pt not_active IP Right Cessation
- 2005-12-15 SI SI200531547T patent/SI1828137T1/sl unknown
- 2005-12-15 CA CA002591397A patent/CA2591397A1/en not_active Abandoned
- 2005-12-15 PL PL05820528T patent/PL1828137T3/pl unknown
- 2005-12-15 US US11/793,482 patent/US8124775B2/en not_active Expired - Fee Related
- 2005-12-15 JP JP2007545948A patent/JP5132317B2/ja not_active Expired - Fee Related
- 2005-12-15 RU RU2007127127/04A patent/RU2393151C2/ru not_active IP Right Cessation
- 2005-12-15 ES ES05820528T patent/ES2384980T3/es not_active Expired - Lifetime
- 2005-12-15 PT PT05820528T patent/PT1828137E/pt unknown
- 2005-12-15 DK DK05820528.7T patent/DK1828137T3/da active
- 2005-12-15 MX MX2007007188A patent/MX2007007188A/es active IP Right Grant
- 2005-12-15 AT AT05820528T patent/ATE555097T1/de active
- 2005-12-15 AU AU2005315770A patent/AU2005315770B2/en not_active Ceased
- 2005-12-16 TW TW094144588A patent/TW200635900A/zh unknown
- 2005-12-16 AR ARP050105313A patent/AR055011A1/es not_active Application Discontinuation
- 2005-12-16 PE PE2005001475A patent/PE20060767A1/es not_active Application Discontinuation
- 2005-12-16 DO DO2005P000259A patent/DOP2005000259A/es unknown
- 2005-12-19 GT GT200500377A patent/GT200500377A/es unknown
- 2005-12-20 UY UY29276A patent/UY29276A1/es not_active Application Discontinuation
-
2007
- 2007-06-18 IL IL184008A patent/IL184008A/en not_active IP Right Cessation
- 2007-06-18 CU CU20070140A patent/CU23452B7/es not_active IP Right Cessation
- 2007-06-18 MA MA30003A patent/MA29100B1/fr unknown
- 2007-06-19 NO NO20073146A patent/NO20073146L/no not_active Application Discontinuation
-
2012
- 2012-02-16 US US13/398,290 patent/US20120142728A1/en not_active Abandoned
- 2012-06-29 CY CY20121100588T patent/CY1112887T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20060767A1 (es) | 2006-09-10 |
| IL184008A0 (en) | 2007-10-31 |
| US20080255068A1 (en) | 2008-10-16 |
| GT200500377A (es) | 2006-11-09 |
| MX2007007188A (es) | 2007-08-14 |
| AU2005315770B2 (en) | 2011-12-08 |
| DOP2005000259A (es) | 2006-11-15 |
| KR20070090248A (ko) | 2007-09-05 |
| ATE555097T1 (de) | 2012-05-15 |
| AR055011A1 (es) | 2007-08-01 |
| BRPI0519602A2 (pt) | 2009-02-25 |
| JP5132317B2 (ja) | 2013-01-30 |
| CY1112887T1 (el) | 2016-04-13 |
| TW200635900A (en) | 2006-10-16 |
| EP1828137B1 (de) | 2012-04-25 |
| PL1828137T3 (pl) | 2012-09-28 |
| EP1828137A1 (de) | 2007-09-05 |
| AU2005315770A1 (en) | 2006-06-22 |
| MA29100B1 (fr) | 2007-12-03 |
| CU23452B7 (es) | 2009-12-01 |
| NO20073146L (no) | 2007-09-18 |
| UY29276A1 (es) | 2006-07-31 |
| PT1828137E (pt) | 2012-07-04 |
| RU2393151C2 (ru) | 2010-06-27 |
| SI1828137T1 (sl) | 2012-08-31 |
| WO2006063828A1 (de) | 2006-06-22 |
| US8124775B2 (en) | 2012-02-28 |
| US20120142728A1 (en) | 2012-06-07 |
| CA2591397A1 (en) | 2006-06-22 |
| DK1828137T3 (da) | 2012-07-23 |
| RU2007127127A (ru) | 2009-01-27 |
| ES2384980T3 (es) | 2012-07-16 |
| JP2008524145A (ja) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120142728A1 (en) | Chemical compound and its use | |
| US20080194609A1 (en) | Chemical Compound and Its Use | |
| US8227511B2 (en) | Substituted chromanol derivatives and their use | |
| EP1735320B1 (en) | Compounds and methods for treating dyslipidemia | |
| US10759721B2 (en) | Deuterated CFTR potentiators | |
| CZ214497A3 (cs) | Heterocyklicky kondensované pyridiny, způsob jejich výroby, farmaceutické prostředky tyto látky obsahující a jejich použití | |
| EP2318410A2 (en) | New small-molecule pde-10 inhibitors | |
| JP2008524255A (ja) | 化学物質 | |
| EP2646417A1 (en) | Kat ii inhibitors | |
| CN101124206B (zh) | 4-环烷基取代的四氢喹啉衍生物及其作为药物的用途 | |
| HK1117832A (en) | 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments | |
| DE102004061001A1 (de) | Chemische Verbindung und ihre Verwendung | |
| KR100470192B1 (ko) | 안드로겐수용체변조제화합물및방법 | |
| DE102004061002A1 (de) | Chemische Verbindung und ihre Verwendung | |
| DE102004061000A1 (de) | Chemische Verbindung und ihre Verwendung | |
| DE102004060998A1 (de) | Chemische Verbindung und ihre Verwendung | |
| TW202440551A (zh) | 一種THRβ受體激動劑化合物及其製備方法和用途 | |
| DE102004061003A1 (de) | Chemische Verbindung und ihre Verwendung | |
| DE102004060999A1 (de) | Chemische Verbindung und ihre Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |